TX-MAVENIR
14.12.2020 15:02:13 CET | Business Wire | Press release
Mavenir, the industry’s only end-to-end cloud-native network software provider for mobile operators, and Microelectronics Technology Inc. (MTI), a network solutions provider, announced today the general availability of the Evenstar B3 Remote Radio Head (RRH) in collaboration with Facebook Connectivity. The Evenstar B3 RRH will give mobile network operators (MNOs) the ability to accelerate the adoption of Open RAN technology by providing standardized architecture and a modular approach for disaggregated Radio Access Network (RAN) components.
Mavenir and MTI recently completed the end-to-end interoperability testing of the Evenstar B3 RRH and are now lab testing the solution with multiple MNOs around the world. The Evenstar B3 RRH from Mavenir and MTI not only addresses current feature requirements in networks today, but also provides flexibility for future feature upgrades, providing a true Virtualized RAN (vRAN) solution.
Launched earlier this year, the Evenstar program focuses on building general-purpose RAN reference architecture for 4G and 5G networks that are aligned with 3GPP and O-RAN specifications. The Evenstar program also contributes to the Telecom Infra Project (TIP)’s OpenRAN Project Group, working to accelerate the path to commercial deployment of simplified, flexible, disaggregated RAN technologies. RRHs, distribution units (DU), and control unit (CU) software have traditionally been only available as a packaged unit, limiting opportunities to serve suburban and rural locations. By decoupling these components, the Evenstar program enables MNOs to choose best-in-class technology and deploy solutions from an increasing number of technology partners.
“The availability of low cost RRHs based on OpenRAN specifications is key to faster adoption of OpenRAN. We are excited to work with Facebook, TIP and MTI to bring the first 4G/5G OpenRAN-compliant Evenstar radio to market that is generally available for use by the Open RAN community.” said Pardeep Kohli, President & CEO of Mavenir.
“MTI is excited to announce the general availability of the Evenstar RRH. This is a major milestone for MTI and for our partners in the Open RAN ecosystem. We will continue to introduce more products to the Open RAN market and address the needs of different regions.” said Allen Yen, Chairman & CEO of MTI.
The Evenstar B3 RRH is generally available now as part of the Evenstar program, with plans to expand into other Open RAN architectural elements. The Evenstar program will eventually include multiple RRH product SKUs, including FDD B3 (4T4R 4X40W). The RRH architecture is based on O-RAN Alliance Fronthaul specifications based on Split 7.2.
About MTI
Microelectronics Technology Inc. (MTI) is a high-technology company that has specialized in wireless communication product development, manufacturing, and global sales for more than 35 years. Based on core competency in RF/ Microwave, MTI has established a leading position in the fields of Remote Radio Heads, Microwave Radios, Satellite Transceivers and ODUs, Broadband Wireless access products, and Radio Frequency Identification (RFID) readers and modules. With this excellent record of accomplishment, MTI has established valued, long-term partnerships with world-leading partners. MTI now offers a portfolio of products that are O-RAN compliant. For more information, visit: www.mtigroup.com
About Mavenir
Mavenir is the industry's only end-to-end, cloud-native Network Software and Solutions/Systems Integration Provider, focused on accelerating software network transformation for Communications Service Providers (CSPs). Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging innovations in IMS (VoLTE, VoWiFi, Advanced Messaging (RCS)), Private Networks as well as vEPC, 5G Core and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 120 countries, which serve over 50% of the world’s subscribers.
Mavenir embraces disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. For more information, visit: www.mavenir.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom